Abstract
After injury to the central nervous system intrinsic factors such as myelin associated inhibitory factors inhibit cellular and axonal regeneration resulting in permanent disability. Three of these factors (Nogo-A, oligodendrocyte myelin glycoprotein, myelin-associated glycoprotein) bind to a common receptor: the Nogo-66 receptor (NgR1). NgR1 is expressed mainly on neurons and is usually associated in a trimolecular complex. The second member of the complex, LINGO-1, is often connected to NgR1 function and is further found to function independently as a negative regulator of oligodendrocyte proliferation and differentiation. The third member of the NgR complex is either the p75 neurotrophin receptor, TROY, or an as yet unidentified co-receptor. Targeting of factors contained in this complex has been described to lead to the promotion of neurite outgrowth, oligodendrocyte proliferation and differentiation and inhibition of cell death. In the current review, we aim to describe the mechanisms of action of the chemical and biological compounds used in targeting NgR1 and LINGO-1. This will be achieved using three examples: blocking of ligand binding to NgR1 in treatment of spinal cord injury, antibody-mediated inhibition of LINGO-1 to promote oligodendrocyte differentiation in multiple sclerosis, and the use of soluble NgR1 to sequester Abeta peptide in the periphery in Alzheimers disease.
Keywords: Alzheimer's disease, LINGO-1, multiple sclerosis, myelin associated inhibitory factors, nogo receptor, spinal cord injury, central nervous system intrinsic, oligodendrocyte mye-lin glycoprotein, glycoprotein, oli-godendrocyte, sclerosis, chondroitin sulphate proteoglycans, glycosylphosphatidylinositol, hippocampal neurons, Purkinje cells, neurotrophin receptor, hybridization, immunohistochemis-try, oligodendrocyte precursor, myelination, alka-line phosphatase (AP), guanosine triphosphatase, blood-brain barrier, Schwann cell grafts, olfactory nervous system, erythropoietin, minocyclin, intravenous steroids, remyelination, corticospinal tract, thoracic spinal cord, serotonergic axon, amyloid peptide, mutagenesis, Multiple Sclerosi, Interferon-s, glatiramir acetate, glucocorticosteroids, proteolipid protein, Parkinson's disease, B lymphocyte stimulator
Current Medicinal Chemistry
Title: Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Volume: 18 Issue: 2
Author(s): C. L. McDonald, C. Bandtlow and M. Reindl
Affiliation:
Keywords: Alzheimer's disease, LINGO-1, multiple sclerosis, myelin associated inhibitory factors, nogo receptor, spinal cord injury, central nervous system intrinsic, oligodendrocyte mye-lin glycoprotein, glycoprotein, oli-godendrocyte, sclerosis, chondroitin sulphate proteoglycans, glycosylphosphatidylinositol, hippocampal neurons, Purkinje cells, neurotrophin receptor, hybridization, immunohistochemis-try, oligodendrocyte precursor, myelination, alka-line phosphatase (AP), guanosine triphosphatase, blood-brain barrier, Schwann cell grafts, olfactory nervous system, erythropoietin, minocyclin, intravenous steroids, remyelination, corticospinal tract, thoracic spinal cord, serotonergic axon, amyloid peptide, mutagenesis, Multiple Sclerosi, Interferon-s, glatiramir acetate, glucocorticosteroids, proteolipid protein, Parkinson's disease, B lymphocyte stimulator
Abstract: After injury to the central nervous system intrinsic factors such as myelin associated inhibitory factors inhibit cellular and axonal regeneration resulting in permanent disability. Three of these factors (Nogo-A, oligodendrocyte myelin glycoprotein, myelin-associated glycoprotein) bind to a common receptor: the Nogo-66 receptor (NgR1). NgR1 is expressed mainly on neurons and is usually associated in a trimolecular complex. The second member of the complex, LINGO-1, is often connected to NgR1 function and is further found to function independently as a negative regulator of oligodendrocyte proliferation and differentiation. The third member of the NgR complex is either the p75 neurotrophin receptor, TROY, or an as yet unidentified co-receptor. Targeting of factors contained in this complex has been described to lead to the promotion of neurite outgrowth, oligodendrocyte proliferation and differentiation and inhibition of cell death. In the current review, we aim to describe the mechanisms of action of the chemical and biological compounds used in targeting NgR1 and LINGO-1. This will be achieved using three examples: blocking of ligand binding to NgR1 in treatment of spinal cord injury, antibody-mediated inhibition of LINGO-1 to promote oligodendrocyte differentiation in multiple sclerosis, and the use of soluble NgR1 to sequester Abeta peptide in the periphery in Alzheimers disease.
Export Options
About this article
Cite this article as:
L. McDonald C., Bandtlow C. and Reindl M., Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System, Current Medicinal Chemistry 2011; 18 (2) . https://dx.doi.org/10.2174/092986711794088326
DOI https://dx.doi.org/10.2174/092986711794088326 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetic Modification in Neuropathic Pain
Current Pharmaceutical Design EDITOR’S PERSPECTIVE [The Challenges for Drug Development: Cytokines, Genes, and Stem Cells]
Current Neurovascular Research Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Mechanisms of Neural Stem Cell Fate Determination: Extracellular Cues and Intracellular Programs
Current Stem Cell Research & Therapy Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways
Current Neuropharmacology Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants (ASIA) – Animal Models as a Proof of Concept
Current Medicinal Chemistry Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies
Letters in Drug Design & Discovery Neuroprotective Gene Therapy for Parkinson’s Disease
Current Gene Therapy Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry Current Perspectives for the use of Gonane Progesteronergic Drugs in the Treatment of Central Hypoventilation Syndromes
Current Neuropharmacology Structural Approaches to Explain the Selectivity of COX-2 Inhibitors: Is There a Common Pharmacophore?
Current Medicinal Chemistry The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Current Pharmaceutical Design MR-Based In Vivo Analysis of Joint Biomechanics and its Relevance in the Pathogenesis of Osteoarthritis
Current Rheumatology Reviews Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease – A Focused Review
Current Gene Therapy